Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

AACR 2021

10 Apr - 21 May 2021
Virtual
Rare inherited pathogenic germline variants observed in sporadic paediatric neur...
Dr Emily Blauel - Children’s Hospital of Philadelphia, Philadelphia, USA
Rare inherited pathogenic germline variants observed in sporadic paediatric neuroblastoma cases ( Dr Emily Blauel - Children’s Hospital of Philadelphia, Philadelphia, USA )
11 May 2021
MRTX9768: a synthetic lethal-based inhibitor designed to bind the PRMT5 MTA comp...
Dr Matthew Marx - Mirati Therapeutics, San Diego, USA
MRTX9768: a synthetic lethal-based inhibitor designed to bind the PRMT5 MTA complex and target MTAP/CDKN2A-deleted tumours ( Dr Matthew Marx - Mirati Therapeutics, San Diego, USA )
30 Apr 2021
Anti-tumour activity and tolerability of RMC-4630 as a single agent in patients ...
Prof Ravi Salgia - City of Hope, Duarte, USA
Anti-tumour activity and tolerability of RMC-4630 as a single agent in patients with RAS-addicted solid cancers ( Prof Ravi Salgia - City of Hope, Duarte, USA )
26 Apr 2021
Mechanisms of acquired resistance to KRAS G12C inhibition in cancer
Dr Mark Awad - Dana-Farber Cancer Institute, Boston, USA
Mechanisms of acquired resistance to KRAS G12C inhibition in cancer ( Dr Mark Awad - Dana-Farber Cancer Institute, Boston, USA )
26 Apr 2021
CheckMate 816 trial: Nivolumab and platinum-doublet chemotherapy vs chemo as neo...
Dr Patrick M. Forde - Johns Hopkins University, Baltimore, USA
CheckMate 816 trial: Nivolumab and platinum-doublet chemotherapy vs chemo as neoadjuvant treatment for resectable NSCLC ( Dr Patrick M. Forde - Johns Hopkins University, Baltimore, USA )
16 Apr 2021
Phase III randomised trial comparing tebentafusp with investigator’s choice in f...
Dr Jessica Hassel - University Hospital Heidelberg, Heidelberg, Germany
Phase III randomised trial comparing tebentafusp with investigator’s choice in first-line metastatic uveal melanoma ( Dr Jessica Hassel - University Hospital Heidelberg, Heidelberg, Germany )
16 Apr 2021
Randomised phase III study of copanlisib plus rituximab vs rituximab/placebo in ...
Dr Matthew Matasar - Memorial Sloan Kettering Cancer Center, NYC, US
Randomised phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma ( Dr Matthew Matasar - Memorial Sloan Kettering Cancer Center, NYC, US )
16 Apr 2021
Healthy lifestyle may offset risk of lethal prostate cancer in men with high gen...
Dr Anna Plym - Harvard University, Boston, USA
Healthy lifestyle may offset risk of lethal prostate cancer in men with high genetic risk ( Dr Anna Plym - Harvard University, Boston, USA )
15 Apr 2021
SMMART Program: A multi-omics tumour board with a focus on breast cancer
Dr Ben Kong - Oregon Health & Science University, Portland, USA
SMMART Program: A multi-omics tumour board with a focus on breast cancer ( Dr Ben Kong - Oregon Health & Science University, Portland, USA )
13 Apr 2021
PC14586: The first orally bioavailable small molecule reactivator of Y220C mutan...
Dr Melissa Dumble - PMV Pharmaceuticals, Cranbury, USA
PC14586: The first orally bioavailable small molecule reactivator of Y220C mutant p53 in clinical development ( Dr Melissa Dumble - PMV Pharmaceuticals, Cranbury, USA )
13 Apr 2021
Adjuvant therapy with nivolumab combined with ipilimumab vs nivolumab alone in p...
Prof Georgina Long - University of Sydney, Sydney, Australia
Adjuvant therapy with nivolumab combined with ipilimumab vs nivolumab alone in patients with resected stage IIIB-D/IV melanoma ( Prof Georgina Long - University of Sydney, Sydney, Australia )
13 Apr 2021
Clinical validation of a targeted methylation-based multi-cancer early detection...
Dr Eric Klein - Cleveland Clinic, Cleveland, USA
Clinical validation of a targeted methylation-based multi-cancer early detection test ( Dr Eric Klein - Cleveland Clinic, Cleveland, USA )
13 Apr 2021
Safety and efficacy of atezolizumab plus bevacizumab for unresectable hepatocell...
Prof Richard Finn - Geffen School of Medicine at UCLA, Los Angeles, USA
Safety and efficacy of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma ( Prof Richard Finn - Geffen School of Medicine at UCLA, Los Angeles, USA )
13 Apr 2021
Efficacy and safety of selpercatinib in RET fusion-positive cancers other than l...
Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA
Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers ( Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA )
13 Apr 2021
High-quality neoantigens are immunoedited in long-term survivors of pancreatic c...
Prof Marta Luksza - Tisch Cancer Institute, New York, USA
High-quality neoantigens are immunoedited in long-term survivors of pancreatic cancer ( Prof Marta Luksza - Tisch Cancer Institute, New York, USA )
12 Apr 2021